Geode Capital Management LLC recently announced the acquisition of new stake in NRX Pharmaceuticals Inc (NASDAQ:NRXP). The institutional investor has increased its shareholding in the Healthcare company by 8.78% to 0.41 million shares with purchase of 33255.0 shares. This fresh investment now brings its stake to 0.48% valued currently at $0.14 million. In addition, Renaissance Technologies LLC raised its holdings by 0.13 million to 0.16 million shares.
Currently, there are 66.44M common shares owned by the public and among those 56.74M shares have been available to trade.
Insiders at the company have transacted a total of 4 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 4 of these insider trades were purchases, accounting for 405,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in NRX Pharmaceuticals Inc are Vanguard Total Stock Market ETF, AdvisorShares Psychedelics ETF, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market ETF owns 0.98 million shares of the company’s stock, all valued at over $0.34 million. Vanguard Extended Market Index Fu now owns shares totaling to 0.53% of the shares outstanding.
However, the script later moved the day high at 0.4770, up 24.19%. The company’s stock has a 5-day price change of 27.58% and 69.83% over the past three months. NRXP shares are trading -62.07% year to date (YTD), with the 12-month market performance down to -61.38% lower. It has a 12-month low price of $0.22 and touched a high of $1.41 over the same period. NRXP has an average intraday trading volume of 430.48K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 28.06%, 33.85%, and -6.46% respectively.
Institutional ownership of NRX Pharmaceuticals Inc (NASDAQ: NRXP) shares accounts for 4.40% of the company’s 66.44M shares outstanding. Mutual fund holders own 3.11%, while other institutional holders and individual stakeholders account for 33.36% and 1.28% respectively.
It has a market capitalization of $35.86M and a beta (3y monthly) value of 0.92. The earnings-per-share (ttm) stands at -$0.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.36% over the week and 10.52% over the month.
Analysts forecast that NRX Pharmaceuticals Inc (NRXP) will achieve an EPS of -$0.12 for the current quarter, -$0.12 for the next quarter and -$0.32 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.14 while analysts give the company a high EPS estimate of -$0.11. Comparatively, EPS for the current quarter was -$0.16 a year ago. Earnings per share for the fiscal year are expected to increase by 25.41%, and 49.45% over the next financial year.
